Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Olmesartan Medoxomil · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Olmesartan Medoxomil Tablets 40 mg |
| 2 | ACTIVE_COMPARATOR | Benicar® Tablets 40 mg |
| Name | Type | Description |
|---|---|---|
| Olmesartan Medoxomil Tablets 40 mg | DRUG | 40mg, single dose fed |
| Benicar® Tablets 40 mg | DRUG | 40mg, single dose fed |
Inclusion Criteria: * healthy, adult subjects, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days of start of study * received any investigational product...
Olmesartan Medoxomil is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with completed trials evaluating its pharmacokinetic profile. The drug is being developed by Viatris Inc. and has not been approved for any indication.
Olmesartan Medoxomil is being developed by Viatris Inc., a company traded on the NASDAQ under the ticker VTRS. The drug is currently in Phase 1 clinical development, with two completed trials in healthy volunteers. Viatris is responsible for the ongoing clinical program for this investigational small molecule.
Olmesartan Medoxomil is in Phase 1 clinical development. Two Phase 1 trials have been completed, both enrolling healthy volunteers in the United States. The drug remains investigational and has not received regulatory approval. Viatris Inc. is the developer of this small molecule.
Olmesartan Medoxomil has two completed Phase 1 clinical trials. NCT00648219 is a fed study comparing Olmesartan Medoxomil tablets 40 mg to Benicar tablets 40 mg, enrolling 36 healthy volunteers. NCT00649623 is a fasting study with the same design, also enrolling 36 healthy volunteers. Both trials were conducted in the United States.
Olmesartan Medoxomil is being studied as a potential generic equivalent to Benicar. The Phase 1 clinical trials compare Olmesartan Medoxomil tablets 40 mg directly against Benicar tablets 40 mg under both fed and fasting conditions. However, Olmesartan Medoxomil remains an investigational drug and is not yet approved.
Olmesartan Medoxomil is a small molecule being developed by Viatris Inc. The mechanism of action has not been disclosed in the available clinical trial information. The drug is currently in Phase 1 development, with completed studies evaluating its pharmacokinetics in healthy volunteers compared to a reference product.